Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 10/20 | 0.54 |
| ▸ | CA2 | P00918 | 10/20 | 0.54 |
| ▸ | CA12 | O43570 | 6/20 | 0.54 |
| ▸ | CA9 | Q16790 | 6/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22511877 | 0.98 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL31169524 | 0.98 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL7977069 | 0.98 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL1930913 | 0.98 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL1328306 | 0.98 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL31747379 | 0.98 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL31169526 | 0.98 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL19243360 | 0.98 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL4967290 | 0.94 | MAOA (0.68) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL14086303 | 0.92 | MAOA (0.66) | MAOAMAOBTDP1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311880-B | Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infections | 豪夫迈·罗氏有限公司 | 2021-09-03 | — | — | CN | disclosed |
| EP-3478680-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HBV INFECTION | HOFFMANN LA ROCHE (CH) | 2020-04-22 | — | — | EP | disclosed |
| US-20190241559-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HBV INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2019-08-08 | — | — | US | disclosed |
| CN-109311880-A | For treating and preventing hepatitis b virus infected new tetrahydropyridine miazines compound | 豪夫迈·罗氏有限公司 | 2019-02-05 | — | — | CN | disclosed |
| EP-2773633-B1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2017-08-02 | — | — | EP | disclosed |
| EP-3012254-B1 | BIPHENYL DERIVATIVE AND ITS USE FOR TREATING PULMONARY DISORDERS | THERAVANCE RESPIRATORY CO LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-3012254-A1 | BIPHENYL DERIVATIVE AND ITS USE FOR TREATING PULMONARY DISORDERS | Theravance Respiratory Company, LLC (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2246345-B1 | BIPHENYL DERIVATIVES HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE RESPIRATORY CO LLC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-8969571-B2 | Biphenyl derivatives | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140235864-A1 | BIPHENYL DERIVATIVES | THERAVANCE, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-08-26 | — | — | US | disclosed |
| EP-0816378-B1 | Glycopeptide antibiotic amide derivatives | LILLY CO ELI (US) | 2002-04-10 | — | — | EP | disclosed |
| US-5919756-A | CHLORORIENTICIN A ANTIBIOTIC | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| WO-1998000153-A1 | AMIDES | ELI LILLY AND COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
| EP-0816378-A1 | Glycopeptide antibiotic amide derivatives | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| US-4798904-A | ANALGESICS | E. R. SQUIBB & SONS, INC. (US) | 1989-01-17 | — | — | US | disclosed |
| US-4774256-A | MERCAPTO AND ACYLMERCAPTO AMIDES | E. R. SQUIBB & SONS, INC. (US) | 1988-09-27 | — | — | US | disclosed |
| US-4722810-A | Enkephalinase inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1988-02-02 | — | — | US | disclosed |
| EP-0136883-B1 | ENKEPHALINASE INHIBITORS | E.R. Squibb & Sons, Inc. (US) | 1987-11-25 | — | — | EP | disclosed |
| EP-0136883-A2 | Enkephalinase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1985-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235864-A1 | BIPHENYL DERIVATIVES | ADRB1, ADRB2, ADRB3 | MAOA 541/4885MAOB 237/4885TDP1 4658/4885 |
| US-20190241559-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HBV INFECTION | TYMP, RECQL, DPYD | MAOA 2900/4885MAOB 1318/4885TDP1 979/4885 |
| US-20040167167-A1 | Chronic obstructive pulmonary dusease; asthma | ADRB1, ADRB2, ADRA2B | MAOA 605/4885MAOB 306/4885TDP1 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.